A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

摘要: There is a recognizable and urgent need to speed the development application of novel, more efficacious anti-cancer vaccine therapies that inhibit tumor progression prevent acquisition resistance. We have created established portfolio validated peptide epitopes against multiple receptor tyrosine kinases we identified most biologically effective combinations EGFR (HER-1), HER-2, HER-3, VEGF IGF-1R vaccines/mimics selectively receptors signaling pathways. The strategy based on use chimeric conformational B-cell epitope peptides incorporating "promiscuous" T-cell afford possibility generating an enduring immune response, eliciting protein-reactive high-affinity anti-peptide antibodies as potential vaccines mimics act antagonists drive cancer metastasis. In this review will summarize our ongoing studies combinatorial immunotherapeutic strategies synergistically enhance immune-mediated killing aimed at addressing mechanisms resistance for several types.